Cytosolic β-glycosidases for activation of glycoside prodrugs of daunorubicin

Biochemical Pharmacology

Volumn 65, Issue 11, 2003, Pages 1875-1881

  De Graaf, Michelle ^a   Pinedo, Herbert M ^a   Quadir, Razi ^a   Haisma, Hidde J ^b   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anthracyclines; Cancer chemotherapy; Cytosolic glycosidase; Galactoside; Glucoside; Prodrug

Indexed keywords

DAUNORUBICIN; GLYCOSIDASE; GLYCOSIDE; PRODRUG;

ANIMAL CELL; ARTICLE; CATTLE; CELL GROWTH; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KINETICS; LIQUID CHROMATOGRAPHY; MAMMAL; MOLECULAR EVOLUTION; MUTANT; NONHUMAN; PRIORITY JOURNAL;

EID: 0037716395     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00183-7     Document Type: Article

References (24)

1. Bagshawe K.D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer. 56:1987;531-532.
2. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 [published erratum appears in Eur J Cancer 1996 Jan;32A(1):186]. Eur J Cancer 1995;31A:2362-70.
3. Marais R., Spooner R.A., Light Y., Martin J., Springer C.J. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56:1996;4735-4742.
4. Searle F., Bier C., Buckley R.G., Newman S., Pedley R.B., Bagshawe K.D., Melton R.G., Alwan S.M., Sherwood R.F. The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br. J. Cancer. 53:1986;377-384.
5. Austin E.A., Huber B.E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43:1993;380-387.
6. Huber B.E., Richards C.A., Krenitsky T.A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 88:1991;8039-8043.
7. Sharma S.K., Bagshawe K.D., Melton R.G., Sherwood R.F. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys. 21:1992;109-120.
8. Houba P.H., Boven E., van der Meulen-Muileman I.H., Leenders R.G., Scheeren J.W., Pinedo H.M., Haisma H.J. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. Int. J. Cancer. 91:2001;550-554.
9. Fonseca M.J., Storm G., Hennink W.E., Gerritsen W.R., Haisma H.J. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy. J. Gene Med. 1:1999;407-414.
10. Heine D., Muller R., Brusselbach S. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Ther. 8:2001;1005-1010.
11. Weyel D., Sedlacek H.H., Muller R., Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7:2000;224-231.
12. Haisma H.J., Boven E., van Muijen M., de Jong J., van der Vijgh W.J., Pinedo H.M. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer. 66:1992;474-478.
13. Daniels L.B., Coyle P.J., Chiao Y.B., Glew R.H., Labow R.S. Purification and characterization of a cytosolic broad specificity beta-glucosidase from human liver. J. Biol. Chem. 256:1981;13004-13013.
14. Syrigos K.N., Rowlinson-Busza G., Epenetos A.A. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int. J. Cancer. 78:1998;712-719.
15. Leenders R.G., Damen E.W., Bijsterveld E.J., Scheeren H.W., Houba P.H., van der Meulen-Muileman I.H., Boven E., Haisma H.J. Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. 7:1999;1597-1610.
16. Bakina E., Farquhar D. Intensely cytotoxic anthracycline prodrugs: galactosides. Anticancer Drug Des. 14:1999;507-515.
17. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., Ozols R.F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43:1983;5379-5389.
18. De Graaf M., Van Veen I.C., Van Der Meulen-Muileman I.H., Gerritsen W.R., Pinedo H.M., Haisma H.J. Cloning and characterization of human liver cytosolic beta-glycosidase. Biochem. J. 356:2001;907-910.
19. Ishiyama M., Shiga M., Sasamoto K., Mizuguchi M., He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem. Pharm. Bull. 41:1993;1118-1122.
20. Spoelstra E.C., Westerhoff H.V., Pinedo H.M., Dekker H., Lankelma J. The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur. J. Biochem. 221:1994;363-373.
21. Spooner R.A., Martin J., Friedlos F., Marais R., Springer C.J. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther. 7:2000;1348-1356.
22. De Graaf M., Boven E., Oosterhoff D., Van Der Meulen-Muileman I.H., Huls G.A., Gerritsen W.R., Haisma H.J., Pinedo H.M. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br. J. Cancer. 86:2002;811-818.
23. De Groot F.M., Loos W.J., Koekkoek R., Van Berkom L.W., Busscher G.F., Seelen A.E., Albrecht C., De Bruijn P., Scheeren H.W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem. 66:2001;8815-8830.
24. Encell L.P., Landis D.M., Loeb L.A. Improving enzymes for cancer gene therapy. Nat. Biotech. 17:1999;143-147.